Investor Alert
Vascepa® (icosapent ethyl) cardiovascular outcomes study, REDUCE-IT™, topline results are available.
See press release here

DISCOVER

Vascepa®

EXPERIENCED

in lipid science

INVESTOR

relations

Vascepa®

LIPID SCIENCE

investor relations

welcome


therapeutics to improve cardiovascular health

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl) is Amarin's first FDA approved product and is available in the United States by prescription. For more information about Vascepa visit www.vascepa.com.

recent news


24 Sep 2018

REDUCE-IT™ Cardiovascular Outcomes Study of Vascepa® (icosapent ethyl) Capsules Met Primary Endpoint MORE

12 Sep 2018

REDUCE-IT™ Trial Primary Results Accepted for Presentation at 2018 Scientific Sessions of American Heart Association MORE

Stock Information

Symbol:
AMRN (NASDAQ)
Quote:
$19.31
Change:
+1.97
Date:
4:00 PM EDT on Oct 11, 2018
(latest end of day stock price)
Investor
Relations
Executive
Team
Career
Opportunities
Contact
Amarin

Amarin
Corporation

therapeutics to improve
cardiovascular health.

Join Our Mailing List

You may automatically receive Amarin Corporation plc financial information by email.


Click To Subscribe